Sean Ainsworth, CEO of Immusoft, about MPS I, the limits of existing enzyme replacement therapies, and the potential benefits of using engineered B cells to treat people with the rare lysosomal storag...

The Mucopolysaccharidosis I treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, REGENXBIO, Nippon Shinyaku, and Immusoft, among others. DelveInsight’s “Mucopolysaccharidosis Type I Treatment Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the MPS I treatment market, historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Immusoft gave a glimpse on Monday at how the first patient to ever receive an engineered B cell therapy is doing nine months after being dosed, suggesting that the treatment ...

Immusoft has received FDA Rare Pediatric Disease designation for ISP-002, a revolutionary B cell therapy aimed at treating MPS II, a rare genetic disorder.

Immusoft, a pioneering biotechnology firm, is making strides in treating MPS II with its ISP-002 therapy, now with FDA's Orphan Drug Designation.

Immusoft has received FDA Fast Track designation for ISP-001, a groundbreaking engineered B cell therapy targeting MPS I, indicating rapid development for urgent medical needs.

Immusoft has made a groundbreaking advance in gene therapy by successfully re-dosing a patient with ISP-001 for MPS I, showcasing excellent tolerability and safety.

Immusoft is set to present pivotal clinical trial results for engineered B cells aimed at treating MPS I, showcasing innovations in cell therapy.

Immusoft Corporation is set to present groundbreaking findings from its pioneering clinical trial of engineered B cells at WORLDSymposium 2025, promising new treatment avenues.

Immusoft is the world leader in the development of B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our approach, called Immune System Programming (IS...

Our Approach Immusoft is developing a cutting edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP™). ISP enta...

Sean Ainsworth, CEO of Immusoft, about MPS I, the limits of existing enzyme replacement therapies, and the potential benefits of using engineered B cells to treat people with the rare lysosomal storag...

Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme delivery SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug...

Orphan Drug Designation for MPS II builds on Immusoft's clinical progress in MPS I and supports expansion of its engineered B cell platform across multiple indications SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered...

The re-dose of ISP-001 has been well-tolerated, to date, and Immusoft continues to observe positive results SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ -- Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated...

Safety and initial activity of autologous human B cells engineered to express the enzyme iduronidase. Results from a first-in-human clinical trial in subjects with MPS I SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Immusoft of CA, a cell therapy company dedicated to improving the lives of...

Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system. Results from a first-in-human clinical trial in subjects with MPS I SEATTLE, Jan. 27, 2025…

In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I  WV News

Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World's First Engineered B Cell in a Human Clinical Trial  Longview News-Journal

Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World's First Engineered B Cell in a Human Clinical Trial  PR Newswire

Immusoft of CA Inc., a wholly owned subsidiary of Immusoft Corp., has announced that the FDA has granted orphan drug designation to ISP-002, the company’s investigational engineered B-cell therapy for...